{"filing":{"accession_number":"0001193125-26-343407","cik":"0002022626","ticker":"UPB","company_name":"Upstream Bio, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"upb-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/upb-20260811.htm"},"events":[{"id":26848,"run_id":24419,"accession_number":"0001193125-26-343407","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Upstream Bio disclosed its Q2 2026 financial results and business highlights on August 11, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial statements (balance sheet and statements of operations), operating metrics (R\u0026D and G\u0026A expenses, net loss of $39.7 million), and clinical development updates for its lead program verekitug. This is a standard earnings release for a clinical-stage biotech company, filed under Item 2.02 (Results of Operations and Financial Condition).","company_name":"Upstream Bio, Inc.","ticker":"UPB","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28124,"accession_number":"0001193125-26-343407","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Upstream Bio disclosed its Q2 2026 financial results and business highlights on August 11, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial statements (balance sheet and statements of operations), operating metrics (R\u0026D and G\u0026A expenses, net loss of $39.7 million), and clinical development updates for its lead program verekitug. This is a standard earnings release for a clinical-stage biotech company, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:38.192930+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28124,"accession_number":"0001193125-26-343407","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Upstream Bio disclosed its Q2 2026 financial results and business highlights on August 11, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial statements (balance sheet and statements of operations), operating metrics (R\u0026D and G\u0026A expenses, net loss of $39.7 million), and clinical development updates for its lead program verekitug. This is a standard earnings release for a clinical-stage biotech company, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:38.192930+00:00","company_name":"Upstream Bio, Inc.","ticker":"UPB","filing_date":"2026-08-11"}]}